ReviewAmerican journal of translational research2023
The potential of Chinese medicines in the treatment of hyperuricemia.
Review in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.
- Multidimensional therapeutic advantages ofFrontiers in endocrinology · 2026Pooled it
- An evidence mapping study based on systematic reviews of traditional Chinese medicine for hyperuricemia.Frontiers in nutrition · 2026Pooled it
- Network Pharmacology-Based Exploration: Non-Targeted Metabolites ofBiologics : targets & therapy · 2026Article
- A universal fluorescent sensing platform based on "signal switching induced by enzyme catalyzed substrate hydrolysis" for high-throughput discovery of xanthine oxidase inhibitors from traditional Chinese medicine.Frontiers in pharmacology · 2026Article
- Nanotechnology-enabled delivery of luteolin: a comprehensive review on multidisease therapeutic applications.Frontiers in pharmacology · 2026Review
- Phytotherapeutic insights into hyperuricemia: a mechanistic and clinical perspective.Inflammopharmacology · 2025Review
- Advances in external therapies of traditional Chinese medicine for the management of hyperuricemia: a comprehensive review.Frontiers in endocrinology · 2025Review
- Article
- Therapeutic effect of fecal microbiota transplantation on hyperuricemia mice by improving gut microbiota.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The annual incidence of gout is increasing along with lifestyle and dietary changes. Accumulation of urate crystals in joints and tissues when the amount of uric acid exceeds its saturation concentration causes acute inflammation that leads to gout. Reducing the serum uric acid concentration is the key to treating gout. Allopurinol, febuxostat, benzbromarone, and other drugs are effective, but side effects of treatment such as toxicity and recurrence after drug withdrawal cannot be ignored. Recent studies have found that many Chinese medicines are effective and safe, provide durable efficacy, and are associated with low recurrence rates. This article reviews recent investigations of Chinese medicines for lowering uric acid, including components such as berberine, luteolin, and others; single medicines such as
Indexed as
Identifiers
37193181PMC10182497W4376871603What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.